Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Boston Scientific Invests $1.5B for 34% Stake in MiRus, Secures Option to Acquire SIEGEL TAVR Business for Additional $3B

Fineline Cube May 19, 2026
Company Deals

Henlius Biotech Secures Exclusive China Rights to CTFH’s Third-Generation EGFR TKI FHND9041 for NSCLC

Fineline Cube May 19, 2026
Company Deals

Regeneron Partners with Parabilis Medicines on $2.2B Helicon Peptide Platform Deal Targeting “Undruggable” Proteins

Fineline Cube May 19, 2026
Company Deals

Shimai Pharmaceutical Files Hong Kong IPO Prospectus with Advanced T-Cell Engager Pipeline

Fineline Cube May 19, 2026
Company Deals

Youcare Pharmaceutical Commits $147M to Build Nucleic Acid Drug Manufacturing Base in Hangzhou Biopharma Town

Fineline Cube May 19, 2026
Policy / Regulatory

China Tightens Medical Insurance Personal Account Oversight with Mandatory “White List” for Retail Pharmacy Purchases

Fineline Cube May 19, 2026
Company Drug

Bio-Thera Solutions Secures FDA Approval for Golimumab Biosimilars Immgolis and Immgolis Intri

Fineline Cube May 19, 2026
Company Drug

Lundbeck’s Asedebart Receives Japanese Orphan Drug Designation for Congenital Adrenal Hyperplasia and Cushing’s Disease

Fineline Cube May 19, 2026
Company Deals

Shanghai Cell Therapy Group Partners with Nantong Federation for Comprehensive Health Services Platform

Fineline Cube Jun 20, 2023

Shanghai Cell Therapy Group has entered into a partnership with the Nantong Federation of Industry...

Company Deals

Huadong Medicine’s Subsidiary Perfect mRNA Biotechnology Partners with Yoltech Therapeutics

Fineline Cube Jun 20, 2023

China-based Huadong Medicine Co., Ltd (SHE: 000963) subsidiary, Hangzhou Perfect mRNA Biotechnology Co., Ltd, has...

Company

Merck Appoints Marc Horn as China Unit President, Succeeding Allan Gabor

Fineline Cube Jun 20, 2023

Germany-based Merck (NYSE: MRK) has announced the appointment of Marc Horn as its China unit...

Company Drug

Sinocelltech Group Launches Biosimilar Version of AbbVie’s Humira in China

Fineline Cube Jun 20, 2023

China-based Sinocelltech Group Ltd (SHA: 688520) has officially commercialized its biosimilar version of AbbVie’s (NYSE:...

Company Drug

Grand Pharmaceutical Initiates Phase II STARBURST Study for TLX250-CDx in Indication Expansion

Fineline Cube Jun 20, 2023

China-based Grand Pharmaceutical Group Limited (HKG: 0512) has announced the first patient dosing in the...

Company Deals

Novlead Biotech Secures RMB 100 Million in Series B+ Financing for Nitric Oxide Therapy Innovations

Fineline Cube Jun 20, 2023

Novlead Biotech, a specialist in nitric oxide gas detection and treatment based in Nanjing, has...

Company Deals

Guangdong Zhongsheng Pharmaceutical Plans to Raise RMB 600 Million via Private Placement

Fineline Cube Jun 20, 2023

China-based Guangdong Zhongsheng Pharmaceutical Co., Ltd (SHE: 002317) is poised to raise RMB 600 million...

Company Drug

Shanghai Pharmaceuticals’ SPH3127 for Hypertension Gets MNPA Review Acceptance

Fineline Cube Jun 20, 2023

China-based Shanghai Pharmaceuticals Holding Co., Ltd (SHA: 601607) has announced that the National Medical Products...

Company Deals

United Imaging Healthcare Acquires Stake in Apactron for High-End Particle Therapy Technology

Fineline Cube Jun 20, 2023

Shanghai-based United Imaging Healthcare (UIH, SHA: 688271) has announced an investment of RMB 45 million...

Company Deals

Sequanta Technologies Partners with DarkJade Sciences to Establish Organoid Bank and Glioma Project

Fineline Cube Jun 20, 2023

Sequanta Technologies, a leading multi-omics research and clinical service provider based in Shanghai, has announced...

Company Deals R&D

Insilico Medicine Partners with ShanghaiTech University for Tumor Drug R&D Advancement

Fineline Cube Jun 20, 2023

China-based AI-powered drug discovery firm Insilico Medicine has struck a partnership with ShanghaiTech University’s iHuman...

Company Drug

WinHealth Pharma Receives NMPA Approval for Glycerol Phenylbutyrate for Urea Cycle Disorders

Fineline Cube Jun 20, 2023

China-based Hong Kong WinHealth Pharma Group Ltd has announced receiving market approval from the National...

Company Drug

Nanjing Leads Biolabs Receives FDA IND Approval for LBL-033 Phase I/II Clinical Trial

Fineline Cube Jun 19, 2023

China-based Nanjing Leads Biolabs Co., Ltd has revealed that it has received Investigational New Drug...

Company

AstraZeneca Weighs Spinning Off China Business to Shield Against Geopolitical Tensions

Fineline Cube Jun 19, 2023

According to a report from the UK newspaper The Financial Times (FT), AstraZeneca (AZ, NASDAQ:...

Company Drug

TG ImmunoPharma Receives FDA Approval for Phase I Clinical Study of TGI-6 Bispecific Antibody

Fineline Cube Jun 19, 2023

China-based TG ImmunoPharma Co., Ltd has announced that it has received approval from the US...

Company Drug

IASO Bio Receives FDA IND Approval for IASO-782 for Autoimmune Disorders

Fineline Cube Jun 19, 2023

China-based IASO Bio has announced that the US Food and Drug Administration (FDA) has approved...

Company Deals

Adicon Holdings Ltd IPO: A Strategic Move for Growth in Diagnostics

Fineline Cube Jun 19, 2023

Adicon Holdings Ltd (HKG: 9860), a China-based independent clinic laboratory (ICL) service provider, has successfully...

Company Deals

Acotec Scientific Holdings and Boston Scientific Group plc Sign MOU to Broaden Collaboration

Fineline Cube Jun 19, 2023

China-based Acotec Scientific Holdings Ltd (HKG: 6669) has announced a memorandum of understanding (MoU) with...

Company Drug

Aosaikang Pharmaceutical’s ASKB589 Shows Promising Results in Solid Tumor Treatment Study

Fineline Cube Jun 19, 2023

Beijing Aosaikang Pharmaceutical Co., Ltd (SHE: 002755) has revealed the latest results from a Phase...

Company Deals

Jiangsu Hengrui Medicine Cancels Licensing Agreement with Mabworks Citing Market Changes

Fineline Cube Jun 19, 2023

China-based Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276) has announced its decision to cancel a...

Posts pagination

1 … 515 516 517 … 668

Recent updates

  • Bio-Thera Solutions Secures FDA Approval for Golimumab Biosimilars Immgolis and Immgolis Intri
  • GSK Restructures China Vaccine Business with Dedicated Shingrix and Engerix-B Teams
  • Boston Scientific Invests $1.5B for 34% Stake in MiRus, Secures Option to Acquire SIEGEL TAVR Business for Additional $3B
  • Henlius Biotech Secures Exclusive China Rights to CTFH’s Third-Generation EGFR TKI FHND9041 for NSCLC
  • Lundbeck’s Asedebart Receives Japanese Orphan Drug Designation for Congenital Adrenal Hyperplasia and Cushing’s Disease
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Bio-Thera Solutions Secures FDA Approval for Golimumab Biosimilars Immgolis and Immgolis Intri

Company

GSK Restructures China Vaccine Business with Dedicated Shingrix and Engerix-B Teams

Company Deals

Boston Scientific Invests $1.5B for 34% Stake in MiRus, Secures Option to Acquire SIEGEL TAVR Business for Additional $3B

Company Deals

Henlius Biotech Secures Exclusive China Rights to CTFH’s Third-Generation EGFR TKI FHND9041 for NSCLC

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.